(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at ...
(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...
Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of ...
North London Collegiate School (Singapore) has established itself as a leading British international school in Singapore - ...
The latest announcement is out from Annexon Biosciences ( (ANNX) ).
Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with ...
US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
The Sunken Garden is a geometric marvel, with perfectly manicured hedges and colorful blooms arranged in patterns so precise they could make a mathematician weep with joy. It’s the kind of garden that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback